Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Costs and Expenses:
General and administrative	$ 5,727	$ 7,467
Research and development	11,844	18,784
Total Operating Costs and Expenses	17,571	26,251
Loss from Operations	(17,571)	(26,251)
Other Income:
Change in fair value of warrant liability	4,083	10,738
Interest income	67	21
Total Other Income	4,150	10,759
Net Loss	(13,421)	(15,492)
Net Loss Attributable to Non-controlling Interest	(54)	(318)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(13,367)	(15,174)
Preferred Stock Dividends	(243)	(73)
Net Loss Attributable to Common Stockholders	$ (25,291)	$ (22,136)
Net Loss Per Share - Basic and Dilutive	$ (4.06)	$ (6.23)
Weighted average number of shares outstanding during the period - Basic and Dilutive	6,232,442	3,553,316
Series A Preferred Stock [Member]
Other Income:
Preferred Stock Dividends	$ (243)	$ (6,962)
Series B Preferred Stock [Member]
Other Income:
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0	0
Preferred Stock Dividends	$ (11,681)	$ 0